Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ucb pharma sa-nv - piracetam 1200 mg - film-coated tablet - 1200 mg - piracetam 1200 mg - piracetam

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - piracetam 800 mg - film-coated tablet - 800 mg - piracetam 800 mg - piracetam

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - piracetam 1200 mg - film-coated tablet - 1200 mg - piracetam 1200 mg - piracetam

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - piracetam 1200 mg - powder for oral solution - 1200 mg - piracetam 1200 mg - piracetam

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - piracetam 2400 mg - powder for oral solution - 2400 mg - piracetam 2400 mg - piracetam

Malta - English - Medicines Authority

ucb pharma sa 60 allee de la recherche, b-1070 brussels, belgium - piracetam - film-coated tablet - piracetam 800 mg - psychoanaleptics

United States - English - NLM (National Library of Medicine)

e. fougera & co., a division of fougera pharmaceuticals inc. - diflorasone diacetate (unii: 7w2j09scwx) (diflorasone - unii:t2dhj9645w) - diflorasone diacetate 0.5 mg in 1 g - diflorasone diacetate cream usp, 0.05% is a high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. diflorasone diacetate cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - diflorasone diacetate (unii: 7w2j09scwx) (diflorasone - unii:t2dhj9645w) - diflorasone diacetate 0.5 mg in 1 g - topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. use of topical corticosteroids, including diflorasone diacetate ointment may increase the risk of posterior subcapsular cataracts and glaucoma. cataracts have been reported in postmarketing experience with the use of topical diflorasone diacetate products. glaucoma, with possible damage to the optic nerve, and increased intraocular pressure have been reported in postmarketing experience with the use of topical dermal corticosteroids. avoid contact of diflorasone diacetate ointment with eyes. advise patients to report any visual symptoms.

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - diflorasone diacetate (unii: 7w2j09scwx) (diflorasone - unii:t2dhj9645w) - diflorasone diacetate 0.5 mg in 1 g - topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. use of topical corticosteroids, including diflorasone diacetate emollient cream may increase the risk of posterior subcapsular cataracts and glaucoma. cataracts have been reported in postmarketing experience with the use of topical diflorasone diacetate products. glaucoma, with possible damage to the optic nerve, and increased intraocular pressure have been reported in postmarketing experience with the use of topical dermal corticosteroids. avoid contact of diflorasone diacetate emollient cream with eyes. advise patients to report any visual symptoms.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - ethynodiol diacetate (unii: 62h10a1236) (ethynodiol - unii:9e01c36a9s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - ethynodiol diacetate 1 mg - ethynodiol diacetate and ethinyl estradiol tablets usp, 1 mg/35 mcg are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization and progestogen implants and injections, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year  ‡ method (1) typical use § (2) perfect use ¶ (3) (4) chance # 85 85 spermicides Þ 26 6 40 periodic abstinence 25 63    calendar 9    ovulation method 3    sympto-thermal ß 2    post-ovulation 1 withdrawal 19 4 cap à    parous women 40 26 42    nulliparous women 20 9 56 sponge    parous wo